CPC 405

Drug Profile

CPC 405

Latest Information Update: 17 Apr 2001

Price : $50

At a glance

  • Originator Questcor Pharmaceuticals
  • Class Anti-ischaemics; Cytoprotectives; Small molecules
  • Mechanism of Action Adenosine deaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cerebral ischaemia; Ischaemic heart disorders

Most Recent Events

  • 17 Apr 2001 Discontinued-Preclinical for Ischaemic heart disorders in USA (Unknown route)
  • 17 Apr 2001 Discontinued-Preclinical for Cerebral ischaemia in USA (Unknown route)
  • 20 Dec 1999 Cypros Pharmaceutical has merged with RiboGene to form Questcor Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top